CliffBio
small molecule

PREMPHASE 14/14

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

Loss of exclusivity—loss of exclusivity
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand namePREMPHASE 14/14
Active ingredientESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
Strength0.625MG,0.625MG;N/A,5MG
Dosage formTABLET
RouteORAL-28
ModalitySmall molecule
FDA approvalNovember 1995
Marketing statusRX

More from Wyeth

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.